Bad phosphorylation as a target of inhibition in oncology-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bad phosphorylation as a target of inhibition in oncology

Published:2018-02 Issue: Volume:415 Page:177-186
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Bui Ngoc-Linh-Chi,Pandey Vijay,Zhu Tao,Ma Lan^ORCID,Basappa ,Lobie Peter E.

Funder

The Cancer Science Institute of Singapore

National Research Foundation and Ministry of Education, Singapore

National Research Foundation, Singapore

National Medical Research Council of Singapore

The Chinese Academy of Sciences President's International Fellowship Initiative

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference161 articles.

1. The evolving war on cancer;Haber;Cell,2011

2. Molecularly targeted cancer therapy: some lessons from the past decade;Huang;Trends Pharmacol. Sci.,2014

3. Targeted therapy: comprehensive review;RL;Prog. Palliat. Care,2009

4. Antineoplastic Treatment and Renal Injury: An update on renal pathology due to cytotoxic and targeted therapies;Troxell;Adv. Anatomic Pathology,2016

5. N.C. Turner, J.S. Reis-Filho, Genetic heterogeneity and cancer drug resistance, Lancet Oncol., 13 e178–e185.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combining Mitomycin C with inhibition of BAD phosphorylation enhances apoptotic cell death in advanced cervical cancer;Translational Oncology;2024-11

2. An 8-aminoquinoline-naphthyl copper complex causes apoptotic cell death by modulating the expression of apoptotic regulatory proteins in breast cancer cells;European Journal of Pharmacology;2024-09

3. Digital spatial profiling identifies the tumor center as a topological niche in prostate cancer characterized by an upregulation of BAD;Scientific Reports;2024-08-31

4. Matrine Enhances the Antitumor Efficacy of Chidamide in CTCL by Promoting Apoptosis;Recent Patents on Anti-Cancer Drug Discovery;2024-04-02

5. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRASG12D-mutant pancreatic ductal adenocarcinoma;Cell Death & Disease;2024-02-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3